Immunopathogenesis of M.tb Infection and TB in Brazil

Similar documents
The MODS Assay for Detection of TB and TB Drug Resistance: A Multi-center Study

Research Article Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014

Prevalence of depression among patients with suspected tuberculosis at the Health Center of Duque de Caxias, Rio de Janeiro, Brazil

TB Contact Investigation

7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No

Non-commercial use only

The first National TB Prevalence Survey Rwanda 2012

Carlos Fioravanti / Brazil Story also available at in Portuguese.

Tuberculosis and HIV: Renewed Challenge

Single Nucleotide Polymorphisms (SNPs) of the TNF-a (-238/-308) gene among TB and non TB patients: Susceptibility markers of TB occurrence?

Major Article. Rev Soc Bras Med Trop 51(5): , Sep-Oct, 2018 doi: /

Ongoing Research on LTBI and Research priorities in India

MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit

GLI Partners Meeting 18 th April Ivor Langley (LSTM) & Afrânio Kritski (Rede-TB)

TUBERCULOSIS CONTACT INVESTIGATION

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Assessment of a clinical score for screening suspected pulmonary tuberculosis cases

Clinical Evaluation of the Microscopic-Observation Drug-Susceptibility Assay for Detection of Tuberculosis

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Tuberculosis in children: gaps and opportunities

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Clinical Practice Guideline

Fiocruz the National Contact Point in Health

TUBERCULOSIS. Pathogenesis and Transmission

Effectiveness of Highly Active Antiretroviral Therapy (HAART) Used Concomitantly With Rifampicin in Patients with Tuberculosis and AIDS

Overview of Contact Investigation Guidelines

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Please describe the laboratory facilities available in your research institute, including the items listed below (if applicable):

Title:Evaluating HBsAg rapid tests performance in different biological samples from low- and high infection rates settings & populations

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

Low Incidence of Colonization and No Cases of Disseminated Mycobacterium avium Complex Infection (DMAC) in Brazilian AIDS Patients in the HAART Era

Identifying TB co-infection : new approaches?

Low expression of antigen-presenting and costimulatory molecules by lung cells from tuberculosis patients

TB in Corrections Phoenix, Arizona

Contact Investigation Overview

Higher risk for myelopathy development among HTLV-I / HIV-I coinfected subjects

CTRIUMPh Pediatric Biomarker Substudy. IMPAACT TB Scientific Committee Meeting 30 TH May 2017

The Interplay between Zika and other flaviviruses: overview and results from Brazil

Studies and interventions in animals: Ecoepidemiology of leptospirosis in urban slums

ALTERED EX VIVO MONOKINE PRODUCTION RELATED TO HEALTHY ADULTS.

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Mapping cancer, cardiovascular and malaria research in Brazil

Immunology of TB and its relevance to TB Control

Northwestern Polytechnic University

2017/2018 Annual Volunteer Tuberculosis Notice

AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK

Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials

Biomarkers for Tuberculosis. Robert S. Wallis, MD, FIDSA Senior Director, Pfizer

TB Contact Investigation Basics

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service

Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN

A TOLLIP DEFICIENCY ALLELE, RS , IS ASSOCIATED WITH LNCRNA TOLLIP-AS1 EXPRESSION, T-CELL MEMORY PHENOTYPE, AND INCREASED TB SUSCEPTIBILITY

Zincum metallicum controls tissue inflammation in mice infected by Trypanosoma cruzi

Diabetic Immunopathy and TB

Contact Investigation

TB BASICS: PRIORITIES AND CLASSIFICATIONS

PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

TB Outbreak Investigation in Fishery Workers, Maryland. Cassandra Althauser PHASE Internship Maryland Department of Health and Human Hygiene

Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective

Jessica Quintero, BAAS October 20, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil

INDEX CASE INFORMATION

New Standards for an Old Disease:

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Health Systems Research at Imperial College London

Qian Gao Fudan University

Case Report Development of Cutaneous Leishmaniasis after Leishmania Skin Test

MEMORANDUM. Re: Guidance for follow-up of newly-arrived Individual with a Class B1 Tuberculosis Extrapulmonary Tuberculosis

Protective and Pathologic T Cell Response in Cutaneous and Mucosal Leishmaniasis

Major Article. CD8+ T cells in situ in different clinical forms of human cutaneous leishmaniasis

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine

Diagnosis of HIV-Associated Tuberculosis

Yolanda González, Claudia Carranza, Marco Iñiguez, Martha Torres, Raul Quintana, Alvaro Osornio, Carol Gardner, Srijata Sarkar, and Stephan Schwander

Vaccine Preventable Respiratory Infections and Tuberculosis

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Current challenges in HIV care from a Brazilian cohort perspective

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

MISMS Latin America Influenza Meeting and Training Workshop June 25-28, 2012 Estelar Hotel Miraflores Lima, Peru

Communicable Disease Control Manual Chapter 4: Tuberculosis

Photo : Sylvie Ricard. The state of TB in Nunavik

Submitted electronically to:

Hospital Geral de Nova Iguaçu HGNI (HIV Family Care Center) José Henrique Pilotto, MD PHD Principal investigator and CRS leader - Site 5097

Tuberculosis & Refugees in Philadelphia

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TOG The Way Forward

Contact Tracing and Active Case Finding: Underused Tools to Reduce the Burden of TB in Children

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Food baskets given to tuberculosis patients at a primary health care clinic in the city of Duque de Caxias, Brazil: effect on treatment outcomes*

Better Diagnostics for Tuberculosis: A Bolder Vision for TB Control. Peter M. Small, MD Senior Program Officer

Next Generation TB Diagnostics An Update from BMGF. Lee Pyne-Mercier

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Transcription:

3rd Annual RePORT International Meeting Pestana Rio Atlantica Hotel Rio de Janeiro September 12 & 13 2017 Immunopathogenesis of M.tb Infection and TB in Brazil Alexandre Silva de Almeida BSc MSc PhD Post-Doctoral Research Fellow Federal University of Rio de Janeiro (UFRJ)

This information is current as of November 4, 2013. Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity Alexandre S. Almeida, Patrícia M. Lago, Neio Boechat, Richard C. Huard, Luiz C. O. Lazzarini, Adalberto R. Santos, Marcelo Nociari, Hongxia Zhu, Beatriz M. Perez-Sweeney, Heejung Bang, Quanhong Ni, Jie Huang, Andrea L. Gibson, Vera C. Flores, Lorena R. Pecanha, Afrânio L. Kritski, José R. Lapa e Silva and John L. Ho J Immunol 2009; 183:718-731; Prepublished online 17 June 2009; doi: 10.4049/jimmunol.0801212 http://www.jimmunol.org/content/183/1/718 Supplementary Material References Subscriptions Permissions Email Alerts http://www.jimmunol.org/content/suppl/2009/06/18/jimmunol.080121 2.DC1.html This article cites 77 articles, 40 of which you can access for free at: http://www.jimmunol.org/content/183/1/718.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscriptions Submit copyright permission requests at: http://www.aai.org/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc

Objective The aim of the Biomarkers project was to discover relevant biomarkers for distinction of Latent and active Tuberculosis (acquisition of infection, progression from infection to disease) that could be used in clinical practice as well as for the evaluation of new drugs or regimens, new vaccines or new surveillance tools. Identify new Biomarkers candidates Patients at T0 Household Contacts at T0 Cohort 1 Guadalupe/RJ (2012-2015) TB Patients Household Contacts 74 individuals 73 individuals 147 individuals analyzed Methodology Serum/ 4-6 Months Plasma Blood RNAm PBMC s Household Contacts at T4+ Household & Patients 2 Years after treatment Cohort 2 UFRJ (2012-2014) TB Patients Household Contacts 7 individuals 62 individuals 69 individuals analyzed

Experimental design Reanalysis of Genes Differentially Expressed (GDE's) 2012 Different studies Data Baks from the Gene M.tb Expression Ominibus (GEO) Sel. and obtaining data from Mycobacterium tuberculosis (GEO) GSE11199 GSE25534 Software Estatístico R GSE31348; GSE36238 Creation of the expression sets GSE28623 Statistical Reanalysis E-GEOD-19491; E-GEOD-19443; E-GEOD-19442 Sel criteria from GDE s for reanalysis P value Adjusted P value Adjusted 0,05 Log Fold Change >1 Graphics, Diagrams & GDE s spread sheets Interview with contact and / or the patient Guadalupe RJ Sample collection in PAXGENE RNA Extraction at FIOCRUZ RJ cdna Log Fold Change > or <1 Selection of potential Biomakers Synthesis of 86 Primers Total de 181 Biomarkers candidates cdna Pré amplification General analysis of clusters P valor Ajustado <0,1-0,05 Análise do dado Bruto de Expressão Statistical Software R"

Table 1. Demographic, clinical data of all COHORT 1 subjects at the time of diagnosis. Clinical Charactheristics Features TST- TST+ TB P.value Age Years 35 (23.6) 38 (25.7) 74 (50) 0,8681 38 (IQR=26.5) 41 (IQR=29.25) 40 (IQR=20.75) Gender Male 10 (6.8) 12 (8.1) 47 (31.8) 2e-04 Female 25 (16.9) 26 (17.6) 27 (18.2) Sputum Smear microscopy Neg 20 (13.5) 1 Pos 54 (86.5) TB Culture 1 5 (3.4) 1 2 + 32 (20.1) Time of Cough Weeks 8 (IQR=9) 0,7087 Cavity No 14 (9.5) Yes 46 (31.1) Treatment Outcome Defaulting 11 (7.4) cure 47 (31.8) Death 2 (1.4) Sociodemographic, clinical and laboratorial characteristics of the household contacts (TST-, n=35), latent tuberculosis infection (TST+, n=38) patients, and active tuberculosis (TB, n=74) patients in the cohort 1.

Table 2. Demographic, clinical data of all COHORT 2 subjects at the time of diagnosis. Clinical Charactheristics Features TST- TST+ TB P.value 22 (31.9) 40 (58) 7 (10.1) Age Years 43.5 (IQR=29.75) 43 (IQR=21.75) 52 (IQR=7) 0,0786 Gender Male 7 (10.1) 14 (20.3) 3 (4.3) 0,8699 Female 15 (21.7) 26 (37.7) 4 (5.8) Acid Fast Bacilli 0 2 (2.9) 1 1 + 3 (3.2) TST Convertors 4 (5.8) Sociodemographic, clinical and laboratorial characteristics of the household contacts (TST-, n=22), latent tuberculosis infection (TST+, n=40) patients, and active tuberculosis (TB, n=7) patients in the cohort 2.

1 Cohort 1. Biological process: Immune response, Gene expression, Apoptosis, Angiogenesis Gene Pathways: IFN, Zinc, Cytokines

Cohort 2 Same way of mrna expression as in the cohort 1 2.

Cohort 1 & 2 Group analysis performed LTBI x TST TB x TST TB x TST + 1 2. 1 2; 1 2;

Cohort 1 1. 38)

Cohort 1

Conclusions Our evidences demonstrate that reanalysis of microarray data sets of human studies provided a potential approach to study Biomarkers in active tuberculosis. There is an increase in the VEGFA mrna expression and protein synthesis detected in blood samples of active TB individuals There is a positive correlation and a positive ratio between VEGFA/CCL2 at protein levels suggesting a potential for the determination of active TB disease.

MCTI-CNPq/MS-SCTIE-DECIT-SVS-DST-Aids N º 30/2014 & FOA: PA-14-328: Administrative Supplements for U.S. - Brazil Biomedical Collaborative Research N º 30/2014 TITLE: BIOMARKER DISCOVERY FOR TUBERCULOSIS INFECTION AND DISEASE Key persons in Brazil: José Roberto Lapa e Silva (PI), Afranio Lineu Kritski, Martha Maria de Oliveira, Milton Ozório Moraes, Valeria Rolla, Marcelo Ribeiro Alves, Eduardo Netto, Marcelo dos Santos Cordeiro, Alexandre Silva de Almeida Key persons in the USA: Timothy R. Sterling, Catherine McGowan, Bryan Shepherd, Megan Turner, Amondrea Blackman, Cathy Jenkins, Spyros Kalamns, Chris Fiske Two major sites Vanderbilt Division of Infectious Disease UFRJ Multidisciplinary laboratory of Reseach Outline of Evaluation at Vandy-Rio study Aim 1 - Identify Mtb-specific CD4+ T cells in 4 patient groups and measure activation/exhaustion markers. Aim 2 - Assess Treg function in the different patient groups this would expand on our previous paper where we found that people with EPTB have increased frequency of Treg and increased T cell activation (as measured by CD38 and HLA-DR)

Hospital Universitário Clementino Fraga Filho - UFRJ Alexandre S de Almeida Caio César José Roberto Lapa e Silva Martha Maria Oliveira Afranio L Kritski Anna Karlla Almeida Alessandra Ferreira Coelho Samantha Ribeiro Brum Elisangela Silva Mayla Gabryele M. de Melo Fundação Oswaldo Cruz - FIOCRUZ Milton Ozório Moraes Bruno Andrade Marcelo Ribeiro Alves Leonardo Araujo Carlos Diego de Andrade Ferreira Paula Mello Maria Helena Saad Policlínica Augusto Amaral Peixoto em Guadalupe SMS-RJ & Secrataria de Saúde de Duque de Caxias Adriana Silva Resende Moreira Ivina Soares Isabela Oliveira Mônica Flores Ricks Vaderbilt University Nashville /TN Timothy R Sterling Cristina Fiske Marina Cruvinel Amondrea Blackman Louise Barnet Mary Kirby Spyros Kalams Catherine McGowan Financial Suports: Bolsa PNPD -CAPES/FAPERJ Bolsa PosDoc Senior - FAPERJ Pesquisa em Doenças Negligenciadas - CNPq Projeto Equipamento Solidário FAPERJ NIH CNPq FOA: PA-14-328

THANKS ABOVE ALL TO: WHO/Jean Chung